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INTRODUCTION
The authors welcome the publication of a special
issue in Parasitology pertaining to the control of
schistosomiasis in Africa. In this editorial, we sum-
marize the key features of the visionaryWorldHealth
Assembly Resolution 54.19, passed some 8 years ago.
Indeed, this resolution endorsed large-scale distri-
bution of anthelminthic drugs for morbidity control
of schistosomiasis and soil-transmitted helmin-
thiasis, which should become the wider, global strat-
egy of preventive chemotherapy in 2006. Looking
into the future, the authors propose to further foster
eﬀective partnerships bringing to fruition ﬁeld-level
implementation and health policies adaptable to dif-
ferent epidemiological and socio-economic settings
of the developing world, and conclude that a scale-up
and an upgrade in the ﬁght against schistosomiasis
are feasible and mandatory for the international
community.
WORLD HEALTH ASSEMBLY RESOLUTION 54.19
In May 2001, the World Health Assembly (WHA)
Resolution 54.19 set a milestone for schistosomiasis
control and placed this disease ﬁrmly back on the
international health agenda. Recognizing the ex-
perience of large-scale programmes in Brazil, China,
Egypt and Morocco in proving that chemotherapy
with praziquantel was an eﬀective way to control
schistosomiasis-associated morbidity, the WHA
urged member states to follow these examples to
scale-up control of the disease throughout endemic
regions. Resolution 54.19 was the global endorse-
ment of a strategic approach that had been developed
and presented in two scholarly articles published in
the Transactions of the Royal Society of Tropical
Medicine and Hygiene, the ﬁrst one in the early 1990s
(Savioli, Bundy and Tomkins, 1992) and the second
one a decade later in 2002 in its present strategic
format and the necessary supporting scientiﬁc evi-
dence (Savioli et al. 2002).
WHA Resolution 54.19 advocated for the control
of schistosomiasismorbidity in highly endemic areas,
and urged countries to attain a target of regular treat-
ment of ‘‘at least 75% and up to 100% of all school-age
children at risk of morbidity by 2010 ’’.
Regular administration of single-dose, safe anthel-
minthic drugs was the ﬁrst key point of the above
strategy: administration of praziquantel at regular
intervals – so as to keep the worm burden in in-
dividuals low and conﬁned – was identiﬁed as the
most eﬀective tool to control morbidity rapidly in
spite of continued high schistosomiasis transmission.
Coverage was the second key point : setting a cover-
age goal ensured that treatment interventions were
not isolated and focal, but full public health inter-
ventions which could be implemented at the national
level. The third key point was the target population:
the resolution recommended a focus on children
of school-age, as they represent the group at highest
risk of heavy worm burden and, in a context of
low availability of resources, the easiest one to
reach (through school-based drug distribution in-
terventions), and consequently the group in which
the highest impact of treatment both in terms of
coverage and likelihood to reverse the pathology
would occur.
With this policy ﬁrmly set in place, and technical
guidance ensured by WHO, progress has been made
since 2001; several governments – thanks to backing
from a number of international organizations, donor
foundations, bilateral institutions and non-govern-
mental organizations (NGOs) – responded to the call
for action. Themost signiﬁcant, perhaps, was amajor
commitment of the Bill and Melinda Gates Foun-
dation to kick-start control activities at the national
level. With a grant of US$ 30 million, the Schisto-
somiasis Control Initiative (SCI) was launched in
2002 that aided the scale-up of schistosomiasis and
soil-transmitted helminthiasis control in six selected
African countries (Garba et al. 2006; Kabatereine
et al. 2006). As a consequence, the number of schisto-
somiasis treatments increased in those countries
from 530000 in 2003 to 12.84 million by the end
of 2005 (Frost and Reich, 2008). As summarized
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by Fenwick and colleagues in their Schistosomiasis
Control Initiative (SCI) review published in this
special issue of Parasitology, another 8.17–10.72
million treatments have been administered annually
from 2006 to 2008 (Fenwick et al. 2009). Several
additional sub-Saharan African countries have also
embarked on large-scale treatment for schistoso-
miasis with the availability of donated praziquantel.
While much still needs to be done, activities against
schistosomiasis are a reality in many endemic coun-
tries, and several least developed countries, including
Burkina Faso and Uganda (Gabrielli et al. 2006;
Zhang et al. 2007; Toure´ et al. 2008), have already
attained the 2010 target.
STEPS TOWARDS INTEGRATION OF
HELMINTHIASES CONTROL
Apossible fourth key point ofWHAResolution 54.19
was the integration of disease control interventions.
Recognizing that geographical overlap of schisto-
somiasis and soil-transmitted helminthiasis is the
rule rather than the exception, the resolution ad-
dressed the two diseases together. Even though co-
administration of praziquantel with either of the two
benzimidazole drugs, albendazole and mebendazole,
was not overtly recommended in the resolution,
the scientiﬁc and ethical justiﬁcation for this was
already available and an opportunity for synergy ex-
isted (Olds et al. 1999). Indeed, Olds and colleagues
showed that co-administration was both safe and
potentially more cost-eﬀective, as it took advantage
of a single drug delivery channel, thereby better
streamlining resources. It therefore became the re-
sponsibility of WHO to advocate and encourage
countries on the need to concurrently control mor-
bidity due to schistosomiasis and soil-transmitted
helminthiasis.
Today, in most countries where praziquantel is
distributed, albendazole or mebendazole are also in-
cluded in the intervention package, thus potentially
enhancing the impact in terms of improved health
status. Albendazole is the most widely used anthel-
minthic drug, since it is recommended for use in
interventions against soil-transmitted helminthiasis
(as an alternative to mebendazole), and against lym-
phatic ﬁlariasis (in combination with ivermectin or
diethylcarbamazine). When given alone, albendazole
or mebendazole can be distributed from one year of
age onwards and, in 2007 over 170million preschool-
age children and school-age children were adminis-
tered with at least one dose of these drugs (WHO,
2009). It is likely that the number of children treated
with either albendazole or mebendazole will further
increase.
The idea that one drug can combat more than
one disease, and conversely, that an intervention can
be used to distribute more than a single drug, was
one of the key concepts that inspired, in October
2006, the launch of a new global strategy against
helminthic diseases (WHO, 2006). The term ‘pre-
ventive chemotherapy’ was coined and the strategy
for helminthiasis was reviewed and endorsed by ex-
perts during an Informal Consultation held inMarch
2006, at the WHO headquarters in Geneva. The key
message was for a broader, co-ordinated, and more
rational use of anthelminthic drugs in control inter-
ventions: the new strategy does not supersede or
replace the recommendations of WHA Resolution
54.19, rather puts the control of schistosomiasis
within a broader picture, promoting integrated con-
trol of helminthic diseases in areas of co-endemicity,
so as to optimize resources and maximize public
health impact (Brady, Hooper and Ottesen, 2006;
Hotez et al. 2006, 2007; Lammie, Fenwick and
Utzinger, 2006).
By advocating for a co-ordinated use of anthel-
minthic drugs and promoting a further integration
among disease control programmes, preventive
chemotherapy reiterates the key message of WHA
Resolution 54.19 and expands its domain of appli-
cation to two additional diseases, thus covering all
the four major human helminthiases (in addition to
schistosomiasis and soil-transmitted helminthiasis,
also lymphatic ﬁlariasis and onchocerciasis). The
decision-making process for treatment (what drugs
to use, how frequently) relies on algorithms that take
into account the endemicity and co-endemicity of
diseases, such that medicines can be given alterna-
tively and safely (WHO, 2006). Drugs against three
of the four diseases currently covered by preventive
chemotherapy have also been safely co-administered
in co-endemic areas of Zanzibar and Nigeria (Eigege
et al. 2008; Mohammed et al. 2008). However, due
to the risk of side-eﬀects and the diﬃculties of ad-
ministering a large number of tablets to individuals,
triple drug administration with ivermectin, alben-
dazole and praziquantel should be accompanied
by precautionmeasures before scale-up is fully rolled
out (WHO, 2006).
Preventive chemotherapy is an adaptable tool that
could also include one of the elements of the SAFE
strategy against blinding trachoma, namely the dis-
tribution of azithromycin (note: the SAFE strategy
consists of eyelid surgery (S), antibiotics to treat
the community pool of infection using azithromycin
(A), facial cleanliness (F) and environmental change
(E)), as well as the distribution of vaccines, micro-
nutrients and commodities such as insecticide-
treated nets, etc. Coordinated implementation of
programmes has also been given impetus and mo-
mentum by the advocacy for the control of neglected
tropical diseases (Hotez et al. 2006, 2007), leading to
signiﬁcant pledges of support from the American and
British governments, as well as the Bill and Melinda
Gates Foundation, working through the Global
Network for Neglected Tropical Disease Control
(GNNTDC), the pharmaceutical industry, and
L. Savioli and others 1678
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182009991181
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 11 Jul 2017 at 09:54:57, subject to the Cambridge Core terms of use, available at
many not-for proﬁt organizations. With more re-
sources for disease control andmany potential actors,
coordinated implementation becomes imperative.
AN EVOLVING TARGET OF CONTROL
But what is the present evolution – with respect to
control of schistosomiasis – from recommendations
generated by the WHA resolution set forth in May
2001 (WHO, 2002) to the recommendations of the
‘preventive chemotherapy’ guidelines published in
October 2006? Thresholds of prevalence for imple-
mentation of large-scale interventions remain un-
changed. What has evolved is a further expansion,
where necessary, of the target population, so as to
include additional high-risk groups such as older
preschool children (over 4 years of age and o94 cm
high), and adults considered to be at risk, from special
groups (pregnant and lactating women; individuals
with occupations involving contact with infested
water), to entire communities living in highly-
endemic areas (WHO, 2006). Children of school-age
(enrolled and non-enrolled) continue to be the major
target group, to be reached not only through schools,
but through a multiplicity of delivery channels and
because of the association between genital schisto-
somiasis and HIV infection, adolescent girls in areas
endemic for urinary schistosomiasis, are also an im-
portant group to be targeted for treatment (Kjetland
et al. 2006, 2008).
The rationale for such an expansion of the target
population was the recognition that population
groups other than school-age children are also at risk
of developing morbidity. Young adults have active
inﬂammatory lesions that should be treated while
still reversible, so as to prevent further development
of morbidity, and older preschool-age children in
high transmission areas may have already built up
signiﬁcant worm burdens that require treatment
(Stothard and Gabrielli, 2007). It is also a matter of
unperceived burden of disease: even if overt, disease-
speciﬁc pathology cannot be readily appreciated,
many individuals infected with schistosomiasis will
suﬀer from ‘subtle morbidity’, such as anaemia,
chronic pain and exercise intolerance, negatively af-
fecting their productive and social life (King and
Dangerﬁeld-Cha, 2008).
An additional reason for expanding the target
population is linked to the increased aﬀordability of
praziquantel on the international market; the com-
mitment by Merck KGaA to provide free of charge
200 million tablets through the Merck Praziquantel
Donation Program (MPDP), in partnership with
WHO, is a remarkable example in this regard.
However, the current supply of praziquantel is not
suﬃcient to treat all those at risk of morbidity due to
schistosomiasis. More needs to be done to ensure the
availability of praziquantel either through increased
donations or through purchase with the additional
resources pledged for the control of neglected trop-
ical diseases.
With respect to delivery channels, it is up to
national governments and their implementation
partners to identify the best way to make health ser-
vices available to citizens. School-based distribution,
the main channel currently used for delivery of pra-
ziquantel, is an excellent option where school enrol-
ment is high, but might not be suﬃcient where less
than 50% of children attend school, and where an
expansion of the target population beyond the
school-age population is the case. Moreover, in
areas where drug administration campaigns against
onchocerciasis and lymphatic ﬁlariasis are in place
through community-based interventions, it may be
more rational to add praziquantel to these delivery
channels rather than to advocate for an additional
system for distributing drugs. Some countries have
used various delivery channels in a complementary
manner to successfully reach high coverage of at-risk
populations.
FORGING SUSTAINABLE CONTROL
INTERVENTIONS
Beneﬁts resulting from control and the eventual
elimination of schistosomiasis and the other neglec-
ted tropical diseases far exceed the costs of im-
plementing public health measures against them,
with cost-beneﬁt ratios showing that regular anthel-
minthic treatment delivered through the health and
educations system and other existing or new in-
novative delivery channels is possibly the ‘best buy’
available today in public health.
The WHO will continue to advocate for the con-
trol of neglected tropical diseases, as well as to collect
scientiﬁcally sound and up-to-date information that
can be translated into feasible and adaptable guide-
lines for ﬁeld use. In this rapidly-changing scenario,
WHO endeavours to foster partnerships that seek
solutions for ﬁeld-level implementation and trans-
lation into policies adaptable to diﬀerent epidemio-
logical and socio-economic settings.
Recommendations and strategies would remain a
pure theoretical exercise without substantial invest-
ment. Even if the 75% target set for 2010 by WHA
Resolution 54.19 will most likely be missed, we are
convinced that the overall balance is not negative,
because the purpose of setting a threshold is not only
that of reaching such a threshold, but rather that of
fostering mobilization of resources and involvement
of committed partners around a common objective.
This indeed has happened, and the ‘spirit ’ of the
resolution has therefore not been betrayed: today,
an increasing number of governmental institutions
and NGOs, with expanding support from the pri-
vate sector, are recognizing that neglected tropical
diseases, including schistosomiasis, are a serious
obstacle to the economic development of endemic
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countries. This inequity of health in sub-Saharan
Africa is becoming more widely known and in so
doing is fostering a greater international willingness
to alleviate these intolerable burdens.
In our view, the future of the ﬁght against schisto-
somiasis comprises two major steps. On the one
hand, a quantitative step, that is, a marked expansion
of treatment coverage of populations in need through
a global access to praziquantel, i.e. more tablets and
more ﬁnancial resources to distribute them, with the
aim of reaching the target set by WHA Resolution
54.19 as soon as possible. The involvement of the
private sector will be crucial in this regard, and we
hope that the example given byMerck KGaA will be
instrumental in rallying other ‘men of good will ’
around this cause. The other step is the qualitative
upgrade of the combat: the successful achievement of
control of morbidity and mortality through preven-
tive chemotherapy in many endemic foci opens the
way to a more ambitious objective, that of producing
a signiﬁcant impact on transmission rates and
therefore achieving elimination of schistosomiasis.
In order to do so, we need to build on the experiences
of Cambodia, China, Morocco, Tunisia and a num-
ber of Caribbean countries and territories that sig-
niﬁcantly managed to curb transmission rates by
upgrading their control arsenal and gearing it up
for elimination. In other words, we need the proof-
of-principle that transmission of schistosomiasis –
especially that due to Schistosoma haematobium and
S. intercalatum – can indeed be interrupted in set-
tings such as Sa˜oTome´ and Prı´ncipe, Zanzibar or the
Sahelian plateaus of West Africa. WHO is ready to
face this challenge and is happy to welcome new and
old travel companions wishing to embark on this
journey. We see control and elimination of schisto-
somiasis in Africa as the core of the expansion of the
ﬁght against neglected tropical diseases worldwide:
if the battle is won here, all other continents are
doomed to follow.
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